What is the mechanism of action of this treatment?

The most common treatments for HIV infection involve antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP). ART uses a combination of drugs that inhibit various stages of the HIV life cycle, such as reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors, to reduce the viral load in the body. PrEP, which is similar to the intervention being studied in the trial, involves taking a daily pill containing tenofovir and emtricitabine to prevent HIV infection. These treatments are essential for HIV patients as they help manage the infection, prevent the progression to AIDS, and reduce the risk of transmitting the virus to others.

What side effects are associated with this type of intervention?

The most common treatments for HIV, particularly those used in PrEP (Pre-Exposure Prophylaxis), include antiretroviral medications such as tenofovir and emtricitabine. Known side effects of these medications can include gastrointestinal issues like nausea and diarrhea, headaches, and fatigue. In some cases, more serious side effects such as kidney problems and bone density loss may occur. It is important for patients to discuss these potential side effects with their healthcare provider to ensure proper management and monitoring.

What prior FDA approvals exist?

The FDA has approved several antiretroviral drugs for the treatment and prevention of HIV infection. For pre-exposure prophylaxis (PrEP), Truvada (emtricitabine/tenofovir disoproxil fumarate) and Descovy (emtricitabine/tenofovir alafenamide) are commonly used. These drugs help prevent HIV infection in high-risk individuals. For treatment, various ART regimens are available, including integrase inhibitors like bictegravir, nucleoside reverse transcriptase inhibitors (NRTIs) like tenofovir and emtricitabine, and protease inhibitors. These treatments are often combined to form effective regimens for managing HIV infection.

What other types of research exist?

Promising alternatives to PrEP-use promotion by siblings include: 1) Peer-led HIV medication adherence interventions, where trained individuals living with HIV facilitate adherence support, as seen in the 'Ready' intervention. 2) Individual and couples-based adherence counseling, which has been effective in the Partners PrEP Study. 3) Technology-based interventions, such as electronic pill bottle monitoring and unannounced home-based pill counts, which provide objective adherence measures and can be coupled with intensified counseling if adherence falls.

← Back to Search

Entre Herman@s Program for HIV Prevention

N/A

Recruiting

Led By Homero del Pino, PhD, MS

Research Sponsored by Charles Drew University of Medicine and Science

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 90 days

Summary

This trial aims to reduce HIV rates in Latino men who have sex with men by training their siblings to discuss PrEP, a medication that prevents HIV. PrEP is a medication that helps prevent HIV. The study looks at how discussing PrEP compares to discussing other health topics. By promoting PrEP through family support, the trial hopes to increase its use and lower HIV incidence.

Who is the study for?

This trial is for Latino men under 40 who have sex with men, are HIV-negative, haven't used PrEP recently or at all, and are missing certain vaccines. They must be open to discussing healthcare with a sibling and meet specific criteria like not being in a monogamous relationship with an HIV-negative partner.

What is being tested?

The study compares two approaches: one where siblings encourage their gay brothers to use PrEP (a medication to prevent HIV), and another where they talk about getting vaccinated against COVID, Hepatitis A/B, or MPOX instead.

What are the potential side effects?

Since this trial focuses on behavioral intervention rather than medication side effects aren't the main concern. However, discussions around sensitive health topics could potentially cause emotional discomfort.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 90 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~90 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of participants that get vaccinated

Number of participants that start using PrEP

Secondary study objectives

Number of participants who increase their willingness to get vaccinated

Number of participants who increase their willingness to use PrEP

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: PrEP PromotionExperimental Treatment1 Intervention

Group II: Vaccine PromotionPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for HIV infection involve antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP). ART uses a combination of drugs that inhibit various stages of the HIV life cycle, such as reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors, to reduce the viral load in the body. PrEP, which is similar to the intervention being studied in the trial, involves taking a daily pill containing tenofovir and emtricitabine to prevent HIV infection. These treatments are essential for HIV patients as they help manage the infection, prevent the progression to AIDS, and reduce the risk of transmitting the virus to others.

The information-motivation-behavioral skills model of antiretroviral adherence and its applications.Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.